Skip to main content

Table 1 Patient demographics at baseline

From: Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

  n %
83
Age, median and range 49 (22–78)
Tumor size, median (mm) and range 30 (20–80)
Clinical nodal status
 N0 40 48.2
 N1 30 36.1
 N2 8 9.6
 N3 1 1.2
 Nx 4 4.9
Hormone receptor status
 Negative 26 31.3
 Positive 57 68.7
Menopausal status
 Pre-menopausal 54 65.1
 Post-menopausal 29 34.9
Tumor stage
 II 65 78.3
 III 18 21.7
Histologic grade
 1 5 6.0
 2 28 33.7
 3 32 38.6
 Unknown 18 21.7